The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Olaparib, which is taken as tablets, is already available on the NHS. A class of cancer drug known as a PARP inhibitor, it ...

Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of -2.27% and 18.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Kim Leadbeater, MP for Spen Valley, reacts during a demonstration in support of assisted dying outside the British parliament after lawmakers voted in favour of the assisted dying law, in London ...

No other corporate actions details are available.